Patients with narcolepsy type 1 continue to experience residual disease burden despite guideline-recommended therapy
However, orexin-targeted therapies are showing promising results in trials... 📈
>> Selective hypocretin receptor agonists, designed to directly restore orexin signalling <<
📺 Sleep Medicine expert, Prof. Yves Dauvilliers takes us through the evolution of narcolepsy type 1 care in this case-based animated video
Programme endorsed by ANC & Reference Centre for Narcolepsy and Rare Hypersomnias
Supported by an Independent Educational Grant from Takeda
Show more
